# Neuroaxonal Injury in Acute HIV Infection and Following Immediate Antiretroviral Therapy.

- **DOI:** [10.1093/infdis/jiaf583](https://doi.org/10.1093/infdis/jiaf583)
- **Rating:** Sound (3.0 out of 5)
- **Verdict:** A valuable long-term CSF biomarker study identifies neuroaxonal injury after acute HIV, but its causal conclusion about ART exceeds the observational design.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1093%2Finfdis%2Fjiaf583

## Key claims

1. CSF NFL was elevated (ie, >UNL) in 15%, 8%, and 7% of RV254 participants at weeks 0, 24, and 48 + respectively, versus 2% among PWoH.
   - Support: Supported
   - Type: Primary finding
   - Basis: directly reported frequencies, limited by convenience controls and sample-based follow-up comparisons
   - Location: Abstract Results; Results, CSF Biomarker Outcomes
2. RV254 participants demonstrated higher CSF NFL than PWoH at pre-ART AHI (P < .001), and post-ART weeks 24 (P < .001) and 48 or later (week 48+, P = .003).
   - Support: Supported
   - Type: Secondary
   - Basis: consistent group differences, though optional sampling and repeated observations limit precision
   - Location: Abstract Results; Results, CSF Biomarker Outcomes
3. During AHI, elevated CSF NFL was associated with later Fiebig stages (III-V) (P = .034), higher CSF HIV RNA (P = .012) and a smaller difference between HIV RNA in the plasma and CSF (P = .002).
   - Support: Supported
   - Type: Secondary
   - Basis: reported exploratory associations from a small elevated-NFL subgroup without multiplicity adjustment
   - Location: Abstract Results; Results, Factors Associated with Abnormal CSF NFL During AHI; Table 2
4. The findings also indicate that ART is insufficient to provide complete neuroprotection for all PWH, even with the earliest initiation following transmission.
   - Support: Tentative
   - Type: Secondary
   - Basis: the observational cohort lacks a treatment-timing or untreated counterfactual
   - Location: Conclusion

## Strengths

- **Rare long-term acute-HIV CSF dataset** CSF NFL is assessed during acute infection and after suppressive ART through week 240, extending the follow-up horizon beyond the studies discussed in the paper.
  - Dimension: contribution
  - Location: Results, CSF Biomarker Outcomes; Discussion, Neuroaxonal Injury During Follow-Up
- **Controlled and blinded biomarker measurement** Samples were analysed by technicians blinded to clinical data, using single reagent batches with intra-assay coefficients of variation below 10%; NFL was age-adjusted against an established normal limit.
  - Dimension: methodological rigour
  - Location: Methods, Measurements of HIV RNA and Biomarkers
- **Relevant limitations explicitly acknowledged** The Discussion identifies limited serial samples, a brief cognitive battery, standard-assay sensitivity, and restricted demographic generalisability, providing important boundaries for interpretation.
  - Dimension: positioning
  - Location: Discussion, limitations paragraph

## Limitations

- **Repeated observations lack statistical modelling** The week-48+ group pools weeks 48, 96, and 240, and 20 participants contributed multiple samples, yet the reported sample-level tests do not account for within-person correlation. This could alter effective sample sizes and P-values.
  - Dimension: methodological rigour
  - Location: Methods, Statistical Analysis; Results, CSF Biomarker Outcomes
- **ART conclusion lacks causal comparator** All cohort participants began ART during acute infection, with no untreated, delayed-treatment, or alternative-treatment counterfactual. The design therefore cannot establish that ART itself is insufficient for neuroprotection.
  - Dimension: methodological rigour
  - Location: Methods, Study Design and Participants; Conclusion
- **Limited clinical and population transfer** Elevated NFL was not associated with the measured cognitive or mood outcomes, and the cohort was 99% male with a median age of 27 in one setting. These features restrict immediate clinical interpretation and wider transferability.
  - Dimension: application pathway
  - Location: Abstract, Methods; Results, Tables 2–3; Discussion, limitations paragraph

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Clean. The reported numbers and statistics are consistent with the stated results.
- **Reporting and transparency:** Noted. Parent-cohort registration is identified, but preregistration of the analytic plan is not reported; the post-ART subgroup analysis is explicitly exploratory.
  - Conflict of interest: not stated · Ethics approval: declared · Data availability: not stated · Code availability: not stated
- **Reference integrity:** Clean
  - 49 references in manuscript
  - 49 of 49 checkable references found in an index
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
